BRPI0415756A - lipólise medicamentosa local, dirigida - Google Patents

lipólise medicamentosa local, dirigida

Info

Publication number
BRPI0415756A
BRPI0415756A BRPI0415756-7A BRPI0415756A BRPI0415756A BR PI0415756 A BRPI0415756 A BR PI0415756A BR PI0415756 A BRPI0415756 A BR PI0415756A BR PI0415756 A BRPI0415756 A BR PI0415756A
Authority
BR
Brazil
Prior art keywords
lipolysis
directed
local drug
adipose tissue
phospholipid
Prior art date
Application number
BRPI0415756-7A
Other languages
English (en)
Inventor
Peter Boderke
Rainer Pooth
Juergen Sandow
Matthias Gossel
Karl-Heinz Nietsch
Gerhard Sattler
Gerhard Vogel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0415756A publication Critical patent/BRPI0415756A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"LIPóLISE MEDICAMENTOSA LOCAL, DIRIGIDA". A presente invenção refere-se a sistemas de fosfolipídio, que contêm pelo menos um fosfolipídio, pelo menos um ácido biliar e água, são apropriados para produção de medicamentos para tratamento de doenças do tecido adiposo e levam à regressão do tecido adiposo proliferado patologicamente.
BRPI0415756-7A 2003-10-24 2004-10-09 lipólise medicamentosa local, dirigida BRPI0415756A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse
PCT/EP2004/011320 WO2005041919A2 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse

Publications (1)

Publication Number Publication Date
BRPI0415756A true BRPI0415756A (pt) 2006-12-19

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415756-7A BRPI0415756A (pt) 2003-10-24 2004-10-09 lipólise medicamentosa local, dirigida

Country Status (14)

Country Link
EP (1) EP1684722B1 (pt)
JP (1) JP2007509085A (pt)
KR (1) KR20060117914A (pt)
CN (1) CN100482211C (pt)
AT (1) ATE418965T1 (pt)
AU (1) AU2004285264A1 (pt)
BR (1) BRPI0415756A (pt)
CA (1) CA2543187A1 (pt)
DE (2) DE10349979B4 (pt)
ES (1) ES2319997T3 (pt)
HK (1) HK1096857A1 (pt)
IL (1) IL174525A0 (pt)
MX (1) MXPA06004081A (pt)
WO (1) WO2005041919A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
US7622130B2 (en) * 2004-05-19 2009-11-24 Los Angeles Biomedical Research Institute at Harbor UCLA-Medical Center Methods and compositions for the non-surgical removal of fat
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
JP5747820B2 (ja) 2009-08-25 2015-07-15 株式会社 メドレックス ホスファチジルコリンの経皮投与組成物とその製造方法
DE102010028365A1 (de) 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
WO2013180253A1 (ja) * 2012-05-31 2013-12-05 テルモ株式会社 ｐＨ感受性担体およびその製造方法、並びに該担体を含むｐＨ感受性医薬、ｐＨ感受性医薬組成物およびこれを用いた培養方法
NZ727407A (en) * 2014-06-27 2018-12-21 Medytox Inc Methods and compositions of bile acids and salts for reduction of fat
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
RU2736974C1 (ru) * 2017-04-21 2020-11-23 Ами Фарм Ко., Лтд. Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
JP6940889B2 (ja) 2018-01-31 2021-09-29 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
US20230157944A1 (en) 2020-06-01 2023-05-25 Cosmed Pharmaceutical Co., Ltd. Beauty microneedle array

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
DE4122744C2 (de) * 1990-08-06 1994-02-03 Nattermann A & Cie Wäßriges Liposomensystem und Verfahren zu seiner Herstellung
DE4308121A1 (de) * 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite

Also Published As

Publication number Publication date
DE10349979B4 (de) 2006-05-18
WO2005041919A2 (de) 2005-05-12
IL174525A0 (en) 2006-08-01
CN100482211C (zh) 2009-04-29
AU2004285264A1 (en) 2005-05-12
JP2007509085A (ja) 2007-04-12
CA2543187A1 (en) 2005-05-12
DE10349979A1 (de) 2005-06-16
HK1096857A1 (en) 2007-06-15
CN1870977A (zh) 2006-11-29
EP1684722A2 (de) 2006-08-02
KR20060117914A (ko) 2006-11-17
ATE418965T1 (de) 2009-01-15
EP1684722B1 (de) 2008-12-31
MXPA06004081A (es) 2006-06-27
DE502004008793D1 (pt) 2009-02-12
WO2005041919A3 (de) 2005-06-23
ES2319997T3 (es) 2009-05-18

Similar Documents

Publication Publication Date Title
HK1096857A1 (en) Medicamentously targeted local lipolysis
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
NO20081527L (no) Anvendelse av flibanserin for behandling av pre-menopausal seksuell lyst forstyrrelser
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
ATE408601T1 (de) Fredericamycin-derivate
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
TW200611695A (en) Pyrrolopyridine derivatives
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
GT200500291A (es) Nuevos heterociclos
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
PL2081910T3 (pl) Nowe związki
EA200970154A1 (ru) Косметические или дерматологические препараты, содержащие n-ацетилцистеин
CY1116840T1 (el) Χρηση 24-norudca
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERZ PHARMACEUTICALS GMBH (DE)

Free format text: TRANSFERIDO DE: SANOFI-AVENTIS DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2275 DE 12/08/2014.